CYTK · Cytokinetics Inc
$74.13
+0.68 (+0.93%)
At close · Aug 14
Market Cap
$10.31B
Shares
139.02M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Blum | Principal Executive Officer | $11,881,456 |
| Jeffrey J. Hessekiel | Executive Vice President, Chief Legal & Administrative Officer | $6,086,217 |
| Fady I. Malik | Executive Vice President, Research and Development | $4,467,066 |
| Andrew Callos | Executive Vice President, Chief Commercial Officer | $3,787,644 |
| Sung H. Lee | Principal Financial Officer | $3,770,807 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Blum | Principal Executive Officer | $14,368,343 |
| Sung H. Lee | Principal Financial Officer | $5,918,931 |
| Fady I. Malik | Executive Vice President, Research and Development | $5,371,389 |
| Andrew Callos | Executive Vice President, Chief Commercial Officer | $4,389,027 |
| Ching W. Jaw | Former Principal Financial Officer^(^ ^)^ | $1,677,170 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Blum | Principal Executive Officer | $8,751,057 |
| Fady I. Malik | Executive Vice President, Research and Development | $4,439,665 |
| Andrew Callos | Executive Vice President, Chief Commercial Officer | $3,198,488 |
| Ching W. Jaw | Former Principal Financial Officer^(^ ^)^ | $2,983,009 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mr. Blum | Principal Executive Officer | $8,547,825 |
| Robert Blum | Principal Executive Officer | $8,547,825 |
| Dr. Malik | Executive Vice President, Research and Development | $3,543,194 |
| Fady I. Malik | Executive Vice President, Research and Development | $3,543,194 |
| Mr. Jaw | Principal Financial Officer | $2,620,594 |
| Ching W. Jaw | Former Principal Financial Officer^(^ ^)^ | $2,620,594 |
| Andrew Callos | Executive Vice President, Chief Commercial Officer | $2,550,548 |
| Mr. Callos | Executive Vice President, Chief Commercial Officer | $2,550,548 |
| Mr. Cragg | Senior Vice President, Chief Human Resources and Administration Officer | $2,174,682 |
| Mr. Schlossberg | Senior Vice President, Legal and General Counsel and Secretary | $1,991,726 |
| Mr. Wong | Vice President, Chief Accounting Officer | $1,073,432 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mr. Blum | Principal Executive Officer | $6,414,999 |
| Mr. Callos | Executive Vice President, Chief Commercial Officer | $3,323,438 |
| Dr. Malik | Executive Vice President, Research and Development | $3,027,889 |
| Mr. Schlossberg | Senior Vice President, Legal and General Counsel and Secretary | $2,327,204 |
| Mr. Jaw | Principal Financial Officer | $2,320,200 |
| Mr. Cragg | Senior Vice President, Chief Human Resources and Administration Officer | $2,232,709 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mr. Blum | Principal Executive Officer | $5,128,696 |
| Dr. Malik | Executive Vice President, Research and Development | $2,312,433 |
| Mr. Schlossberg | Senior Vice President, Legal and General Counsel and Secretary | $1,663,934 |
| Mr. Jaw | Principal Financial Officer | $1,639,626 |
| Mr. Cragg | Senior Vice President, Chief Human Resources and Administration Officer | $1,570,121 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mr. Blum | Principal Executive Officer | $3,475,975 |
| Dr. Malik | Executive Vice President, Research and Development | $1,580,629 |
| Mr. Schlossberg | Senior Vice President, Legal and General Counsel and Secretary | $1,267,473 |
| Mr. Jaw | Principal Financial Officer | $1,120,386 |
| Mr. Cragg | Chief Human Resources and Administration Officer | $1,051,808 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jeffrey J. Hessekiel | Executive Vice President, Chief Legal and Administrative Officer | Appointed | 2025-11-14 |
| James M. Daly | Class III member of the Board | Appointed | 2025-08-20 |
| Robert E. Landry | Class II member of the Board | Appointed | 2025-02-11 |
| Sung Lee | principal accounting officer | Appointed | 2024-12-16 |
| Santo J. Costa | Board of Directors | Resigned | 2024-11-07 |
| Brett Pletcher | Executive Vice President, Chief Legal Officer | Appointed | 2024-08-15 |
| Sandford D. Smith | Board of Directors | Resigned | 2024-05-17 |
| Sung H. Lee | Executive Vice President, Chief Financial Officer | Appointed | 2024-04-26 |
| Ching W. Jaw | Senior Vice President & Chief Financial Officer | Resigned | 2024-02-02 |
| Mark A. Schlossberg | Senior Vice President, Legal, General Counsel and Secretary | Retired | 2022-04-15 |
| John T. Henderson, M.D. | Chairman of the Board | Appointed | 2022-04-08 |
| L. Patrick Gage, Ph.D. | director | Resigned | 2022-04-08 |
| Robert A. Harrington, M.D. | member of the Board | Appointed | 2022-04-08 |
| Robert M. Califf | director | Resigned | 2022-02-16 |
Key facts
CIK
1061983
CUSIP
23282W605
13F (30d)
455 filings
453 filers
Visit website
Investor relations